Late last week Gilead Sciences ($GILD) took another step forward on its fast-paced development program for the oral hepatitis C drug sofosbuvir. The FDA announced that regulators are providing a priority review for the treatment, potentially lopping four months off of the review process. Sofosbuvir has been studied in combination with ribavirin as well as interferon for several types of hep C. And it's expected to play a big role in future combos that will eliminate the need for interferon injections, eliminating many of the side effects that plague patients. Gilead is leading AbbVie ($ABBV), Bristol-Myers Squibb ($BMY) and other biopharma companies which have set their sights on developing next-gen cocktails. Release